Logo image of PYPD

POLYPID LTD (PYPD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PYPD - IL0011326795 - Common Stock

4.34 USD
-0.04 (-0.91%)
Last: 12/31/2025, 8:25:07 PM
Fundamental Rating

2

Overall PYPD gets a fundamental rating of 2 out of 10. We evaluated PYPD against 191 industry peers in the Pharmaceuticals industry. PYPD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PYPD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PYPD has reported negative net income.
PYPD had negative earnings in each of the past 5 years.
In the past 5 years PYPD always reported negative operating cash flow.
PYPD Yearly Net Income VS EBIT VS OCF VS FCFPYPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

PYPD has a worse Return On Assets (-127.48%) than 83.25% of its industry peers.
PYPD has a worse Return On Equity (-222.69%) than 74.35% of its industry peers.
Industry RankSector Rank
ROA -127.48%
ROE -222.69%
ROIC N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PYPD Yearly ROA, ROE, ROICPYPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PYPD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYPD Yearly Profit, Operating, Gross MarginsPYPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PYPD has been increased compared to 1 year ago.
Compared to 5 years ago, PYPD has more shares outstanding
The debt/assets ratio for PYPD has been reduced compared to a year ago.
PYPD Yearly Shares OutstandingPYPD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PYPD Yearly Total Debt VS Total AssetsPYPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

PYPD has an Altman-Z score of -14.99. This is a bad value and indicates that PYPD is not financially healthy and even has some risk of bankruptcy.
PYPD has a worse Altman-Z score (-14.99) than 78.53% of its industry peers.
PYPD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.99
ROIC/WACCN/A
WACCN/A
PYPD Yearly LT Debt VS Equity VS FCFPYPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.57 indicates that PYPD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.57, PYPD is in line with its industry, outperforming 46.60% of the companies in the same industry.
PYPD has a Quick Ratio of 2.57. This indicates that PYPD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PYPD (2.57) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.57
PYPD Yearly Current Assets VS Current LiabilitesPYPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

PYPD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 62.36%, which is quite impressive.
EPS 1Y (TTM)62.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PYPD will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.17% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.72%
EPS Next 2Y31.81%
EPS Next 3Y21.77%
EPS Next 5Y19.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PYPD Yearly Revenue VS EstimatesPYPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
PYPD Yearly EPS VS EstimatesPYPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PYPD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYPD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYPD Price Earnings VS Forward Price EarningsPYPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYPD Per share dataPYPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

PYPD's earnings are expected to grow with 21.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.81%
EPS Next 3Y21.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PYPD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

POLYPID LTD

NASDAQ:PYPD (12/31/2025, 8:25:07 PM)

4.34

-0.04 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners33.79%
Inst Owner Change-95.08%
Ins Owners5.52%
Ins Owner ChangeN/A
Market Cap72.17M
Revenue(TTM)N/A
Net Income(TTM)-34.22M
Analysts82
Price Target12.5 (188.02%)
Short Float %0.48%
Short Ratio0.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.55%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.58%
EPS beat(4)2
Avg EPS beat(4)-4.29%
Min EPS beat(4)-39.67%
Max EPS beat(4)30.58%
EPS beat(8)4
Avg EPS beat(8)-4.32%
EPS beat(12)7
Avg EPS beat(12)5.15%
EPS beat(16)10
Avg EPS beat(16)3.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2%
EPS NQ rev (1m)5.86%
EPS NQ rev (3m)34.43%
EPS NY rev (1m)14.53%
EPS NY rev (3m)14.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.7
P/tB 4.7
EV/EBITDA N/A
EPS(TTM)-2.94
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.92
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.48%
ROE -222.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-141.15%
ROA(5y)-114.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.57
Quick Ratio 2.57
Altman-Z -14.99
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.45%
Cap/Depr(5y)86.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.67%
EPS Next Y56.72%
EPS Next 2Y31.81%
EPS Next 3Y21.77%
EPS Next 5Y19.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.43%
OCF growth 3YN/A
OCF growth 5YN/A

POLYPID LTD / PYPD FAQ

What is the fundamental rating for PYPD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PYPD.


Can you provide the valuation status for POLYPID LTD?

ChartMill assigns a valuation rating of 1 / 10 to POLYPID LTD (PYPD). This can be considered as Overvalued.


Can you provide the profitability details for POLYPID LTD?

POLYPID LTD (PYPD) has a profitability rating of 0 / 10.


What is the expected EPS growth for POLYPID LTD (PYPD) stock?

The Earnings per Share (EPS) of POLYPID LTD (PYPD) is expected to grow by 56.72% in the next year.